We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Domainex Lead Optimization Services Facilitate a new Cancer Drug Discovery Programme

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Domainex Lead Optimization Services Facilitate a new Cancer Drug Discovery Programme"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
Domainex Ltd and a research team at The Institute of Cancer Research (ICR), have unveiled a new development in their collaboration to find a new treatment for breast cancer. Domainex is now set to provide lead optimization services alongside the work being undertaken at the ICR.

Scientists led by the ICR’s Professor Alan Ashworth of the Breakthrough Breast Cancer Research Centre, working in close collaboration with Domainex, have discovered drug-like compounds that inhibit an enzyme from the PARP superfamily, whose expression leads to the survival of breast cancer cells. The programme recently received a £4 million research grant under the Wellcome Trust's Seeding Drug Discovery initiative to finance its implementation.

Domainex will apply its novel LeadBuilder virtual screening technology to design and select chemical compounds suitable for rapid progression. Furthermore, the company will apply its medicinal chemistry expertise to assist the ICR team to develop drug candidates for progression into clinical trials.

Professor Alan Ashworth said: “We are delighted that the research programme is progressing well and look forward to our scientists continuing to work closely with Domainex, utilizing its innovative technologies and skilled staff, in combination with our own expertise, for discovery of improved cancer treatments”.      

The ICR’s Director of Enterprise Dr Susan Bright added: “Today’s announcement is very encouraging and illustrates why the research programme warranted the £4 million grant awarded by the Wellcome Trust. We shall continue to work closely with our collaborative partners in the implementation of the next phase of the project. Another step forward has been taken in specialist drug discovery geared to enhancing the treatment of cancer”.